Boston Scientific's 2026 guidance cut tests its recovery as WATCHMAN weakness, EP share losses and delayed margin gains push a broader rebound toward 2028.
Boston Scientific's cheaper valuation offers upside, but weaker guidance, share losses, higher debt and delayed catalysts favor patience.
Boston Scientific ( BSX ) manufactures medical devices and products used in various interventional medical specialties worldwide, including cardiovascular and surgical categories. On July 29, BSX reported revenue of $5.44 billion for their June quarter, up 7.5% over the same period last year.
| Health Care Equipment & Supplies Industry | Healthcare Sector | Michael F. Mahoney CEO | XFRA Exchange | 101137107 CUSIP |
| US Country | 59,000 Employees | - Last Dividend | 6 Nov 2003 Last Split | 18 May 1992 IPO Date |
Boston Scientific Corporation is a global developer, manufacturer, and marketer of medical devices used in a variety of interventional medical specialties. Having begun its operations in 1979, the company has grown to serve a diverse range of medical needs through its two primary segments: MedSurg and Cardiovascular. With its headquarters in Marlborough, Massachusetts, Boston Scientific is committed to improving patient health by providing cutting-edge solutions that address complex medical conditions and enhance the quality of life for patients worldwide.